131 related articles for article (PubMed ID: 28332573)
41. Receptor tyrosine kinase inhibitors as anti-angiogenic agents.
Kim DW; Lu B; Hallahan DE
Curr Opin Investig Drugs; 2004 Jun; 5(6):597-604. PubMed ID: 15242247
[TBL] [Abstract][Full Text] [Related]
42. Design, synthesis and characterization of potent microtubule inhibitors with dual anti-proliferative and anti-angiogenic activities.
Zhang H; Fang X; Meng Q; Mao Y; Xu Y; Fan T; An J; Huang Z
Eur J Med Chem; 2018 Sep; 157():380-396. PubMed ID: 30099258
[TBL] [Abstract][Full Text] [Related]
43. Discovery of Novel Antiangiogenic Marine Natural Product Scaffolds.
Ebrahim HY; El Sayed KA
Mar Drugs; 2016 Mar; 14(3):. PubMed ID: 26978377
[TBL] [Abstract][Full Text] [Related]
44. Synthesis and biological evaluation of di-aryl urea derivatives as c-Kit inhibitors.
Ravez S; Arsenlis S; Barczyk A; Dupont A; Frédérick R; Hesse S; Kirsch G; Depreux P; Goossens L
Bioorg Med Chem; 2015 Nov; 23(22):7340-7. PubMed ID: 26526740
[TBL] [Abstract][Full Text] [Related]
45. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
[TBL] [Abstract][Full Text] [Related]
46. Discovery of N-(3-((7H-purin-6-yl)thio)-4-hydroxynaphthalen-1-yl)-sulfonamide derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: Synthesis and biological evaluation. Part III.
Xu F; Xu H; Wang X; Zhang L; Wen Q; Zhang Y; Xu W
Bioorg Med Chem; 2014 Feb; 22(4):1487-95. PubMed ID: 24440479
[TBL] [Abstract][Full Text] [Related]
47. Anti-angiogenic activity of thienopyridine derivative LCB03-0110 by targeting VEGFR-2 and JAK/STAT3 Signalling.
Kim BH; Lee Y; Yoo H; Cui M; Lee S; Kim SY; Cho JU; Lee H; Yang BS; Kwon YG; Choi S; Kim TY
Exp Dermatol; 2015 Jul; 24(7):503-9. PubMed ID: 25808463
[TBL] [Abstract][Full Text] [Related]
48. Exploration of N-(2-aminoethyl)piperidine-4-carboxamide as a potential scaffold for development of VEGFR-2, ERK-2 and Abl-1 multikinase inhibitor.
Jin F; Gao D; Wu Q; Liu F; Chen Y; Tan C; Jiang Y
Bioorg Med Chem; 2013 Sep; 21(18):5694-706. PubMed ID: 23932071
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of tumor cell growth and angiogenesis by 7-aminoalkoxy-4-aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors.
Ravez S; Barczyk A; Six P; Cagnon A; Garofalo A; Goossens L; Depreux P
Eur J Med Chem; 2014 May; 79():369-81. PubMed ID: 24747748
[TBL] [Abstract][Full Text] [Related]
50. Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors.
Gracias V; Ji Z; Akritopoulou-Zanze I; Abad-Zapatero C; Huth JR; Song D; Hajduk PJ; Johnson EF; Glaser KB; Marcotte PA; Pease L; Soni NB; Stewart KD; Davidsen SK; Michaelides MR; Djuric SW
Bioorg Med Chem Lett; 2008 Apr; 18(8):2691-5. PubMed ID: 18362070
[TBL] [Abstract][Full Text] [Related]
51. Utilizing combinatorial engineering to develop Tie2 targeting antagonistic angiopoetin-2 ligands as candidates for anti-angiogenesis therapy.
Shlamkovich T; Aharon L; Barton WA; Papo N
Oncotarget; 2017 May; 8(20):33571-33585. PubMed ID: 28422724
[TBL] [Abstract][Full Text] [Related]
52. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
[TBL] [Abstract][Full Text] [Related]
53. Development of a highly-potent anti-angiogenic VEGF8-109 heterodimer by directed blocking of its VEGFR-2 binding site.
Ghavamipour F; Shahangian SS; Sajedi RH; Arab SS; Mansouri K; Aghamaali MR
FEBS J; 2014 Oct; 281(19):4479-94. PubMed ID: 25132001
[TBL] [Abstract][Full Text] [Related]
54. Potent Pan-Raf and Receptor Tyrosine Kinase Inhibitors Based on a Cyclopropyl Formamide Fragment Overcome Resistance.
Zhang Y; Wang L; Zhang Q; Zhu G; Zhang Z; Zhou X; Chen Y; Lu T; Tang W
J Chem Inf Model; 2017 Jun; 57(6):1439-1452. PubMed ID: 28485964
[TBL] [Abstract][Full Text] [Related]
55. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
56. Scopoletin, an active principle of tree tobacco (Nicotiana glauca) inhibits human tumor vascularization in xenograft models and modulates ERK1, VEGF-A, and FGF-2 in computer model.
Tabana YM; Hassan LE; Ahamed MB; Dahham SS; Iqbal MA; Saeed MA; Khan MS; Sandai D; Majid AS; Oon CE; Majid AM
Microvasc Res; 2016 Sep; 107():17-33. PubMed ID: 27133199
[TBL] [Abstract][Full Text] [Related]
57. Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking.
Eldehna WM; Fares M; Ibrahim HS; Aly MH; Zada S; Ali MM; Abou-Seri SM; Abdel-Aziz HA; Abou El Ella DA
Eur J Med Chem; 2015 Jul; 100():89-97. PubMed ID: 26071861
[TBL] [Abstract][Full Text] [Related]
58. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
[TBL] [Abstract][Full Text] [Related]
59. Natural product derived receptor tyrosine kinase inhibitors: identification of IGF1R, Tie-2, and VEGFR-3 inhibitors.
Stahl P; Kissau L; Mazitschek R; Giannis A; Waldmann H
Angew Chem Int Ed Engl; 2002 Apr; 41(7):1174-8. PubMed ID: 12491250
[No Abstract] [Full Text] [Related]
60. Molecular modeling studies on series of Btk inhibitors using docking, structure-based 3D-QSAR and molecular dynamics simulation: a combined approach.
Balasubramanian PK; Balupuri A; Cho SJ
Arch Pharm Res; 2016 Mar; 39(3):328-39. PubMed ID: 26699616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
